• Early Access customers and collaborators to present new data at ASHG highlighting the benefits of the UG 100 Platform across several key applications

• Ultima to release an updated reference data set concurrent with ASHG highlighting significant improvements to data quality and performance

Ultima Genomics, Inc., a developer of an innovative new ultra-high throughput sequencing architecture, will present, along with several early access customers, new data across a range of different applications at the American Society of Human Genetics (ASHG) annual meeting on Nov. 1-5, 2023, in Washington D.C.

• Sen Zhao of Baylor College of Medicine will present data generated at Baylor using a UG100 early access instrument in a talk entitled “Clinical utility of deep-RNAseq in Mendelian disorder diagnostics” on Nov. 2, demonstrating how ultra-deep whole transcriptome sequencing of clinical samples reveals isoforms and alternative splicing patterns beyond what is normally seen with the current standard sequencing depth.
• Betty Liu of the Greenleaf lab at Stanford University will highlight the use of Ultima’s technology to perform a systematic investigation of the effects of varying transcription factor (TF) levels on accessibility and gene expression using high-throughput ATAC-seq.
• Watchmaker Genomics will demonstrate gene fusion detection via cost-effective whole transcriptome sequencing using the optimized Watchmaker RNA Library prep kit.
• Ultima will present improvements in germline short variant and copy number variant calling from whole genome sequencing, demonstrating that its sequencing methodology provides a robust and cost-effective method that holds promise for both research and clinical applications. In collaboration with Variantyx, these methods are applied to whole genome sequencing of clinical samples to demonstrate accurate detection of common pathogenic clinical variants.

In conjunction with the conference, Ultima will be releasing a new data set demonstrating significant improvements to the technology made through early access. In particular, the data demonstrates significant improvements in indel accuracy made through a variety of advancements across chemistry and bioinformatics. This data will be publicly available for download from the Company’s website on Thursday, Nov. 2.

To learn more about Ultima and the UG 100, come see us at Booth 1823 and attend our Industry Education Session talk entitled Empowering Genomics at Scale at 3:30 p.m. ET on Thursday, Nov. 2 in Room 140AB. More information about our other talks and posters is available on our events page at https://www.ultimagenomics.com/ashg-2023.

ASHG 2023 Highlights

Industry Education Session: Empowering Genomics at Scale Thursday, Nov. 2 | Room 140AB | Talks 3:30 - 4:30 p.m. ET

• Gilad Almogy, Chief Executive Officer, Ultima Genomics — Introduction and update on progress and commercial launch
• George Vacek, NVIDIA - Acceleration of Deep Learning for Data Processing in Genomics
• Betty Liu, Stanford University (Greenleaf Lab) - A high-throughput, automated ATAC-seq reveals quantitative regulatory effects of transcription factor dosage
• Doron Lipson, Ph.D., Chief Scientific Officer, Ultima Genomics - Comprehensive variant analysis in clinical samples by cost-effective whole genome sequencing

Talks: Thursday, Nov 2 from 9:30 – 9:45 a.m.

• Sen Zhang, Baylor College of Medicine - Clinical utility of deep-RNAseq in Mendelian disorder diagnostics

Poster presentations

Thursday, Nov. 2 from 3 – 5 p.m.

• Sarah Pollack, Ultima Genomics - Comprehensive variant analysis in clinical samples by cost-effective whole genome sequencing

Friday, Nov. 3 from 3 – 5 p.m.

• Betty Liu, Stanford (Greenleaf Lab) - A high-throughput, automated ATAC-seq reveals quantitative regulatory effects of transcription factor dosage
• Doron Shem-Tov, Ultima Genomics - Germline short variants detection from UG100 Sequencing Data

Saturday, Nov. 4 from 2:15 – 4:15 p.m.

• Tammy Biniashvilli, Ultima Genomics - Detection of germline copy number variation from whole genome sequencing on UG100: A cost-effective and robust approach
• Jennifer Pavlica, Watchmaker Genomics - Cost-effective, high-resolution whole transcriptome sequencing for gene fusion detection applications

About Ultima Genomics

Ultima Genomics is unleashing the power of genomics at scale. The Company's mission is to continuously drive the scale of genomic information to enable unprecedented advances in biology and improvements in human health. With humanity on the cusp of a biological revolution, there is a virtually endless need for more genomic information to address biology's complexity and dynamic change—and a further need to challenge conventional next-generation sequencing technologies. Ultima's revolutionary new sequencing architecture drives down the costs of sequencing to help overcome the tradeoffs that scientists and clinicians are forced to make between the breadth, depth and frequency with which they use genomic information. The new sequencing architecture was designed to scale far beyond conventional sequencing technologies, lower the cost of genomic information and catalyze the next phase of genomics in the 21st century. To learn more, visit www.ultimagenomics.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20231031372917/en/